|
Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our results showed that ginsenoside Rg1 markedly reduces proinflammatory cytokines release upon DSS stimulation of mouse dendritic cells, that ginsenoside Rg1 suppresses IL-1β (Interleukin 1 beta) and TNF-α (Tumor necrosis factor alpha) release via up-regulation of NLRP12 (NACHT, LRR and PYD domains-containing protein 12) expression, and that ginsenoside Rg1 significantly decreases the inflammatory response to DSS-induced mouse colitis, as evidenced by increased body weight, reduced colonic damage scores and disease activity index (DAI), and lowered proinflammatory cytokines levels.
|
28605639 |
2017 |
|
Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, miR-206 increased dextran sodium sulphate-induced colitis severity (i.e., increased bodyweight loss, DAI score, colon shrinkage, and MPO activity), which was partially ameliorated by miR-206-antagomir treatment. miR-206-agomir treatment potently suppressed A3AR expression and increased NF-κB signalling and downstream cytokine (TNF-α/IL-8/IL-1β) expression in the mouse colon, in contrast to miR-206-antagomir administration.
|
27893428 |
2017 |
|
Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
We showed worsened colonic inflammation in Atg16l1 deficiency mice in DSS induced murine colitis with increased proinflammatory cytokines of IL-1β and TNF-α.
|
28390705 |
2017 |
|
Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our results show that GLP-1-SSM treatment markedly alleviated the colitis phenotype by reducing the expression of pro-inflammatory cytokine IL-1β, increasing goblet cells and preserving intestinal epithelial architecture in colitis model.
|
27553076 |
2017 |
|
Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In addition, AG inhibited the production of pro-inflammatory cytokines, such as TNF-α, IL-1β, and IL-6, and the protein expression of COX-2 and iNOS in mice with DSS-induced colitis.
|
28695925 |
2017 |
|
Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
MIR301A-knockout mice were resistant to the development of colitis following administration of DSS; their colon tissues expressed lower levels of interleukin 1β (IL1β), IL6, IL8, and tumor necrosis factor than colons of control mice.
|
28193514 |
2017 |
|
Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The extract showed effect in both colitis models reducing the expression of proinflammatory mediators (IL-1β, TNF-α, and iNOS), and improving the intestinal epithelial barrier integrity restoring the expression of ZO-1, MUC-2, and TFF-3.These effects were confirmed in vitro.
|
28731213 |
2017 |
|
Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
SIRT5 Desuccinylates and Activates Pyruvate Kinase M2 to Block Macrophage IL-1β Production and to Prevent DSS-Induced Colitis in Mice.
|
28614718 |
2017 |
|
Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The molecular characterization resulted in identification of Il1β as the major elevated cytokine during early phases of colitis.
|
28796256 |
2017 |
|
Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Mechanistically, enhanced NLRP3 inflammasome expression with elevated IL-1β was a predominant feature during the initiation of colitis with miR-223 deficiency.
|
28487310 |
2017 |
|
Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The effectiveness of drug was evaluated by determination of cytokines (TNFα, IL6 and IL1β) and myeloperoxidase (MPO) activity as well as macroscopic scores and histopathological parameters.Doxepin after i.p. administration was effective to reduce colitis severity through reduction in the macroscopic and microscopic colonic parameters, MPO activity and cytokines levels.
|
28694747 |
2017 |
|
Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Moreover, colonic pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) induced by colitis were dramatically decreased by magnolol.
|
28726741 |
2017 |
|
Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Although the exact aetiology of IBD is unknown, uncontrolled NLRP3 Inflammasome activation has shown to play a major role in the chronic intestinal inflammation and mature IL-1β and IL18 are consistently associated with increased colitis and colitis associated colorectal cancer development.
|
28155620 |
2017 |
|
Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In addition, RA resulted in the reduction of the inflammatory-related cytokines, such as IL-6, IL-1β, and IL-22, and protein levels of COX-2 and iNOS in mice with DSS-induced colitis.
|
28383063 |
2017 |
|
Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Mechanically, reduced NF-κВ DNA phosphorylation activity and downregulated TNF-α, IL-1β, IL-6, IL-17 expressions and myeloperoxidase (MPO) activity were associated with improvement in colitis observed in APS-treated mice.
|
28188801 |
2017 |
|
Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here we further investigated the anti-inflammatory effect of compound 1 in DSS-induced colitis in C57BL/6 and NLRP3(-/-) mice, and revealed the possible modulation by compound 1 of NLRP3 inflammasome-mediated IL-1β release from macrophages.
|
26588861 |
2016 |
|
Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Either exogenous IL-1β or IL-18 ameliorated the colitis with or without reduction in Th2 cytokine expression, respectively.
|
27966619 |
2016 |
|
Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
We demonstrated that innate immune production of IL1β mediates colitis in IL10R-deficient mice.
|
27693323 |
2016 |
|
Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In this article, we show that the novel IL-1 family member IL-36γ was expressed during experimental colitis and human inflammatory bowel disease.
|
26590314 |
2016 |
|
Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our results showed that down-regulation of NLRP12 is required for DSS-induced release of proinflammatory cytokines IL-1β and TNF-α; that PR domain zinc finger protein 1 (also known as Blimp-1) induces NLRP12 down-regulation during DSS-induced proinflammatory response and colitis; and that TLR4 is implicated in the up-regulation of Blimp-1 that led to the down-regulation of NLRP12 expression in DSS-induced colitis.
|
27105524 |
2016 |
|
Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The clinical relevance of these findings was assessed by treating CGD patients who had severe colitis with IL-1 receptor blockade using anakinra.
|
24550444 |
2014 |
|
Colitis
|
0.600 |
Biomarker
|
disease |
CTD_human |
Involvement of TACE in colon inflammation: a novel mechanism of regulation via SIRT-1 activation.
|
24548422 |
2014 |
|
Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Blockade of IL-1β activity by treatment with IL-1R antagonist (IL-1Ra; Anakinra) inhibited colitis acceleration in TLR2/MDR1A double deficiency; intestinal CD11b(+)Ly6C(+)-derived IL-1β production and inflammation entirely depended on MyD88.
|
23636052 |
2013 |
|
Colitis
|
0.600 |
Biomarker
|
disease |
CTD_human |
Elevation of serum IL-1β level due to colitis was also attenuated by both treatments.
|
23810507 |
2013 |
|
Colitis
|
0.600 |
Biomarker
|
disease |
RGD |
Use of butyrate or glutamine in enema solution reduces inflammation and fibrosis in experimental diversion colitis.
|
22969190 |
2012 |